News News Details

Commemorating the 80th Anniversary of the Victory of the Chinese People's War of Resistance Against

Date: 2025-09-03
Views: 0

September 3, 2025 marks the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War. On this important day, which carries great triumph, glorious history, and an indelible spirit, in order to deeply commemorate the revolutionary martyrs and carry forward the great spirit of the Resistance War, the Party Branch Committee of the Communist Party of China at Shenzhen Efung Investment Management Enterprise (Limited Partnership) organized a viewing of the military parade.

Through this event, members observed the remarkable achievements of national development and deepened their understanding of the Chinese Communist Party's role as the mainstay during the Resistance War and the indomitable and great spirit of the Chinese nation.

Image: Party members watching the military parade ceremony.

As the historical scroll slowly unfolds,
Let us collectively remember those heroic and moving years of hardship.

As the bugle for progress sounds once more,
Let us together gather the immense strength of our unity.

As the path to rejuvenation lies before us,
Let us stride together towards an even brighter and more splendid future.

Justice shall prevail! Peace shall prevail! The people shall prevail!



Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务